Durham, NC and Männedorf, Switzerland, April 25, 2025 – BioSkryb Genomics and Tecan Group (SIX Swiss Exchange: TECN), today introduced a high-throughput single-cell workflow, combining BioSkryb’s 384-well format of the ResolveOME™ Whole Genome and Transcriptome Single-Cell Core Kit with …
Joint grant program will provide researchers focused on emerging areas of oncology with powerful multi-omic platforms to drive new discoveries
Durham, NC, and Fremont, CA – April 23, 2025 – BioSkryb Genomics, a pioneer in single-cell and ultra–low-input multi-omic solutions, and Ultima Genomics, a l…
Recently we asked our VP of R&D, Jon Zawistowski, PhD, to share his thoughts on the future of multiomics. He shared the following opinions:
Jon Zawistowski, PhD
VP of R&D, BioSkryb Genomics
“I would posit that most of us, when looking back at our previous genomic or epigenomic datasets from 5-10 …
Earlier this year, Genetic Engineering & Biotechnology News asked experts in multiomics about what trends they are excited for in 2025. Read what several experts, including our CSO Charles Gawad, are excited about in the coming year(s).
Read the full commentary here: 2025 Trends: Multiomics
Charle…
Durham, N.C.– January 8, 2025 – BioSkryb Genomics, a pioneer in single-cell and ultra-low input multiomics is excited to announce the launch of ResolveSEQ MRD, an innovative service offering designed to empower further classification and characterization of the MRD cells for hematologic malignancie…
New partnership will increase access to BioSkryb’s industry-leading single-cell multiomics technology
DURHAM, N.C. – September 26, 2024 - BioSkryb Genomics,a company ushering in the next generation of single-cell technology, today announced a partnership with the Human Cell Atlas (HCA), a global con…
In today's post, we have the pleasure of presenting an exclusive interview with our very own Stephanie Scherer PhD, Manager of Scientific Engagement at BioSkryb Genomics. She is our in-house CRISPR expert and enthusiast, and she will share her insights on why CRISPR is such an important scientific a…
BioSkryb will highlight its new automation-ready ResolveDNA® and ResolveOME™ single-cell core kits, and share new breast cancer research and a spotlight presentation
DURHAM, N.C. – March 28, 2024 - BioSkryb Genomics, a company ushering in the next generation of single-cell technology, will highlight…
New ResolveDNA® and ResolveOME™ single-cell kits generate sequencing-ready libraries in under eight hours
DURHAM, N.C. – March 13, 2024 - BioSkryb Genomics, a company ushering in the next generation of single-cell technology, today announced the commercial launch of its new ResolveDNA Whole Genome a…
BioSkryb to introduce new products and novel applications of industry-leading portfolio that advance the single-cell multiomics field through simultaneous interrogation of DNA, RNA, and targeted proteins from each cell
DURHAM, N.C. – January 30, 2024 - BioSkryb Genomics, a company transforming singl…
